Results 111 to 120 of about 15,373 (177)

Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties. [PDF]

Explor Target Antitumor Ther
Hollinger AM, Bill R.
europepmc   +1 more source

Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2- Advanced Breast Cancer. [PDF]

Drugs
Lei L, Canning M, Sakach E, Lateef A, Kamga L, Abid M, Kalinsky K, Gandhi S.   +7 more
europepmc   +1 more source

Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions. [PDF]

Front Oncol
Alasheev AY, Hamama R, Petersen EV, Maximov PY.   +3 more
europepmc   +1 more source

MicroRNA Signatures of Fulvestrant-Treated Luminal Breast Cancer Cells: Identification of Therapeutic Targets Regulated by <i>miR-374b-5p</i>. [PDF]

Int J Mol Sci
Nagata A, Tomioka Y, Yasudome R, Toda H, Tokunaga T, Nagata Y, Kato M, Shinden Y, Nakajo A, Seki N.   +9 more
europepmc   +1 more source

Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer. [PDF]

Oncologist
Sandoval J, Neven P, Emde A, Bidard FC, Aftimos P, Llombart A, Ciruelos E, Fasching PA, Li H, Campone M, Coersmeyer M, Srock S, Gnant M, Barrios C.   +13 more
europepmc   +1 more source

Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms. [PDF]

Curr Oncol
Abdel-Razeq H, Sharaf B.
europepmc   +1 more source

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial. [PDF]

Clin Cancer Res
Jhaveri K, Rugo HS, Cortés J, Oliveira M, Howell SJ, Dalenc F, Gomez HL, Hu X, Krivorotko P, Loibl S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Zhukova L, Nardone A, Wadsworth I, D'Cruz C, Wantenaar T, Das D, de Bruin EC, Turner NC.   +22 more
europepmc   +1 more source

Precision Endocrine-Based Combinations After CDK4/6 Inhibitor Progression in HR-Positive Metastatic Breast Cancer. [PDF]

Drug Des Devel Ther
Abdel-Razeq H.
europepmc   +1 more source

Adverse Events as a Surrogate of Sufficient Pharmacological Exposure in Metronomic Combination Chemotherapy: Extended Real-World Cohort Analysis of the FulVEC Regimen in Metastatic ER+/HER2- Breast Cancer. [PDF]

Cancers (Basel)
Buda-Nowak A, Lubaś M, Jurczyk M, Kwinta Ł, Michałowska-Kaczmarczyk A, Przywara-Sikora A, Konopka K, Koniewski M, Kadłuczka J, Szczerbak O, Wysocki PJ.   +10 more
europepmc   +1 more source

Hippocampal tissue mechanics are sensitive to fluctuations in oestrogen across the rat oestrous cycle. [PDF]

Brain Commun
Milbocker KA, Williams LT, Vander Wiele SS, Zarate ED, Schwarb H, Van Houten EEW, Corbin EA, Klintsova AY, Johnson CL.   +8 more
europepmc   +1 more source